Accessibility Menu
Stemtech logo

Stemtech(OTC) STEK

Current Price$0.00
Market Cap$216.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-100%
1 Month+0%
Stemtech last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-24
Stemtech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-17
1 month+0%USD 0.002026-06-24
3 month-50%USD 0.002026-04-24
Year to date-87.5%USD 0.002025-12-31
1 year-99.66%USD 0.032025-07-24
3 year-99.78%USD 0.052023-07-25
5 year-100%USD 3.002021-07-22
Since inception-100%USD 3.102021-08-20

Stemtech Financials at a Glance

Market Cap

$216.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.47M

Net Income (TTM)

-$3.84M

EPS (TTM)

-$0.02

P/E Ratio

-0.01

Dividend

$0.00

Beta (Volatility)

2.75 (High)

Price

$0.00

Volume

1,908,328

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.03

Estimated Earnings Date

Mar 31, 2023

STEK News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stemtech

Stemtech makes dietary supplements and skin care for people seeking wellness support. Its products aim to help the body’s natural cell renewal process. These offerings target adults interested in nutrition and healthy aging.

Supplements, Creams, and More: What’s on the Shelf?

  • Dietary Supplements: Products like stemrelease3 and Stemflo support the body’s natural cell functions; main buyers are adults focused on wellness. (No revenue breakdown available)
  • Skin Care: DermaStem and Cellect One creams target consumers seeking skin health and renewal. (No revenue breakdown available)
  • Oral Health: OraStem toothpaste is designed for people wanting oral care with added wellness benefits. (No revenue breakdown available)
  • Pet Nutrition: StemPets, launched in 2025, offers supplements for dogs and cats. (No revenue breakdown available)
  • Distribution Network: Products sold through independent business partners and direct-to-consumer channels, reaching North America, Latin America, and Asia.

Growth Moves: The Company’s Playbook

  • Launched Cellect One Shield HOCL and StemPets in 2025 to expand product lines.
  • Entered Malaysia and Taiwan markets in recent years, growing international reach.
  • Developed direct-to-consumer e-commerce strategy in 2025 to broaden sales channels.
  • Outsourced U.S. order fulfillment and customer service to Mexico in 2023 to cut costs.
  • Pursuing joint ventures for retail and wholesale distribution, with partners funding inventory and operations.

What Makes Stemtech Stand Out?

Stemtech operates globally with a network marketing model and a growing direct-to-consumer approach. The company holds patents for its stem cell nutrition and skin care formulas. Its outsourced operations and focus on niche wellness products help manage costs and target specific consumer groups.

Five Things You Need to Know

  • Net sales were $697,925 in Q2 2025, down from $1,325,800 in Q2 2024.
  • Operating loss improved by 56.5% year-over-year in Q2 2025.
  • Cash flow from operations was $74,952 in Q2 2025, up 142.5% from Q2 2024.
  • Working capital deficit was $6.4 million as of June 30, 2025.
  • Full-time employees: 1; market cap: $365,442; beta: 2.186 (high volatility).

Bottom Line

Stemtech has evolved by expanding products and markets while managing ongoing financial challenges. Its focus on niche wellness and global distribution shapes its current business model.

AI Generated • Apr 16, 2026

Industry

Personal Products

Sector

Consumer Staples

CEO

Charles S. Arnold

Website

www.stemtech.com

Headquarters

Naples, FL 33025, US

STEK Financials

Key Financial Metrics (TTM)

Gross Margin

78.62%

Operating Margin

-105.14%

Net Income Margin

-155.29%

Return on Equity

59.51%

Return on Capital

N/A

Return on Assets

-117.97%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$216.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.17B

Volume

1.91M

Avg. Volume

36.39M

Financials (TTM)

Gross Profit

$1.94M

Operating Income

-$2.60M

EBITDA

-$2.41M

Operating Cash Flow

-$200.19K

Capital Expenditure

$0.00

Free Cash Flow

-$200.19K

Cash & ST Invst.

$256.15K

Total Debt

$2.33M

Stemtech Performance Analysis

Stemtech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,559,3995.5%
20232023-12-31USD 4,921,5317.9%
20242024-12-31USD 5,053,6902.7%
20252025-12-31USD 2,876,380-43.1%
Stemtech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-19.6%
Q32025-09-3022.1%
Q42025-12-31-46.3%
Q12026-03-311.1%
Stemtech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.19-1.3%
20232023-12-31USD -0.07-64.9%
20242024-12-31USD -0.03-51.2%
20252025-12-31USD -0.02-25.2%
Stemtech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3079.0%
Q32025-09-30-157.1%
Q42025-12-31-24.1%
Q12026-03-3177.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$462.96K

-46.7%

Gross Profit

$353.65K

-50.9%

Gross Margin

76.39%

N/A

Market Cap

$216.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$216.90K

N/A

Employees

1

N/A

Net Income

-$1.25M

+13.9%

EBITDA

-$1.11M

+5.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$256.15K

-16.2%

Total Debt

$2.33M

-44.0%

Accounts Receivable

$9.20K

-96.5%

Inventory

$325.70K

+72.9%

Long Term Debt

$0.00

N/A

Short Term Debt

$2.33M

-44.0%

Return on Assets

-1.18%

N/A

Return on Invested Capital

32.17%

N/A

Free Cash Flow

-$425.88K

+40.1%

Operating Cash Flow

-$425.88K

+40.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VRTHFIndigenous Bloom Hemp Corp.
$0.00+0.00%
GRPSTrans American Aquaculture, Inc.
$0.00+0.00%
DYNTDynatronics Corporation
$0.04+0.00%
GEATFRadiko Holdings Corp
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%

Questions About STEK

What is the current price of Stemtech?

Stemtech is trading at $0.00 per share.

What is the 52-week range for Stemtech?

Over the past 52 weeks, Stemtech has traded between $0.00 and $0.03.

How much debt does Stemtech have?

As of the most recent reporting period, Stemtech reported total debt of $4.98M.

How much cash does Stemtech have on hand?

Stemtech reported $256.15K in cash and cash equivalents in its most recent financial results.

What is Stemtech’s dividend yield?

Stemtech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services